Skip to content

Checked

Class IIDrug recallOngoing

Bisoprolol Fumarate and Hydrochlorothiazide tablets recall

Recalled by Unichem Pharmaceuticals USA Inc. of East Brunswick, NJ · FDA report 02/11/2026

Not an official recall notice and may be delayed. Confirm with the manufacturer or the agency.

Class
Class II
Moderate
Status
Ongoing
Recall started
01/21/2026
Distribution
Nationwide

Reason for recall

cGMP Deviations: recall due to not meeting the N-Nitroso Bisoprolol impurity specification limits.

Class II: Use of or exposure to the product may cause temporary or medically reversible health problems, or the chance of serious harm is remote.

Recalled product

Product
Bisoprolol Fumarate and Hydrochlorothiazide tablets, USP, 2.5 mg/6.25 mg, 100-count bottle, Rx Only, Manufactured by: UNICHEM LABORATORIS LTD., Pilerne Ind. Estate, Pilerne, Bardez, Goa 403 511, India, Manufactured for: UNICHEM PHARMACEUTICALS (USA), INC., East Brunswick, NJ 08816, NDC 29300-187-01
Lot and code info
Lot # GBHL24005A, Exp Date: 09/2026
Brand names
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE
Recall number
D-0301-2026
Event ID
98323
Initiated by
Voluntary: Firm initiated

Where it was distributed

US Nationwide and PR.

  • Nationwide

Recall timeline

  1. 01/21/2026Firm started the recall
  2. 01/30/2026FDA classified it as Class II
  3. 02/11/2026Published in the FDA enforcement report

More recalls from Unichem Pharmaceuticals USA

Frequently asked questions

Why was Bisoprolol Fumarate and Hydrochlorothiazide tablets recalled?
cGMP Deviations: recall due to not meeting the N-Nitroso Bisoprolol impurity specification limits.
What does Class II mean?
Class II is FDA's moderate recall category: use of or exposure to the product may cause temporary or medically reversible health problems, or the chance of serious harm is remote.
Where was the recalled product sold?
US Nationwide and PR.
Is this recall still active?
The FDA lists the recall as ongoing. The recall is still in progress.

Source: U.S. Food and Drug Administration, openFDA enforcement report · Last updated 02/11/2026 · Do not rely on openFDA to make decisions regarding medical care